Literature DB >> 637492

Immune response and non-specific immunotherapy in melanoma.

A A El-Domeiri.   

Abstract

Tumour-associated antigens and specific immune response to these antigens have been clearly demonstrated in patients with melanoma. Impaired cellular immune reactions are evident in patients with progressive and disseminated disease. Immunotherapy is used to heighten the host resistance and hence prevent recurrence and spread of the tumour. BCG vaccine has been used to produce nonspecific stimulation of the immune system. Preliminary evaluation of the effect of adjuvant systemic BCG therapy suggests that the treatment may have a beneficial effect on patients with early melanoma.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 637492      PMCID： PMC2491963     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN： 0035-8843            Impact factor:   1.891


  9 in total

1.  Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.

Authors:  F R Eilber; D L Morton; E C Holmes; F C Sparks; K P Ramming
Journal:  N Engl J Med       Date:  1976-01-29       Impact factor: 91.245

2.  Treatment of malignant melanoma by intratumoral injection of BCG.

Authors:  C M Pinsky; Y Hirshaut; H F Oettgen
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

Review 3.  BCG and cancer.

Authors:  R C Bast; B Zbar; T Borsos; H J Rapp
Journal:  N Engl J Med       Date:  1974-06-27       Impact factor: 91.245

4.  Tumor cytotoxicity in vitro by macrophages from mice infected with mycobacterium bovis strain BCG.

Authors:  R P Cleveland; M S Meltzer; B Zbar
Journal:  J Natl Cancer Inst       Date:  1974-06       Impact factor: 13.506

5.  Delayed cutaneous hypersensitivity reactions to autologous extracts of Burkitt-lymphoma cells.

Authors:  L Fass; R B Herberman; J Ziegler
Journal:  N Engl J Med       Date:  1970-04-02       Impact factor: 91.245

6.  Clinical immunologic responsiveness in malignant disease. I. Delayed hypersensitivity reaction and the effect of cytotoxic drugs.

Authors:  M Al-Sarraf; P Wong; S Sardesai; V K Vaitkevicius
Journal:  Cancer       Date:  1970-08       Impact factor: 6.860

7.  Tumor spread and reactivity to DNCB: (2, 4 Dinitro-1 chlorobenzene) skin test.

Authors:  A A el-Domeiri
Journal:  Int Surg       Date:  1972-08

8.  Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease.

Authors:  M G Lewis; R L Ikonopisov; R C Nairn; T M Phillips; G H Fairley; D C Bodenham; P Alexander
Journal:  Br Med J       Date:  1969-09-06

9.  Intralesional BCG in the treatment of metastatic malignant melanoma.

Authors:  M J Mastrangelo; H L Sulit; L M Prehn; R S Bornstein; J W Yarbro; R T Prehn
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860
  9 in total
  2 in total

Review 1.  The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments.

Authors:  Cristina Vajaitu; Carmen Cristina Draghici; Iulia Solomon; Cristina Victoria Lisievici; Alexandra Victoria Popa; Mihai Lupu; Constantin Caruntu; Maria Magdalena Constantin; Vlad Mihai Voiculescu
Journal:  J Immunol Res       Date:  2018-10-17       Impact factor: 4.818

Review 2.  Potential of mRNA vaccines to become versatile cancer vaccines.

Authors:  Shiu-Ying Tsao
Journal:  World J Clin Oncol       Date:  2022-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.